Equities research analysts expect Stemline Therapeutics Inc (NASDAQ:STML) to report earnings per share (EPS) of ($0.34) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Stemline Therapeutics’ earnings, with estimates ranging from ($0.63) to $0.00. Stemline Therapeutics reported earnings per share of ($0.92) during the same quarter last year, which indicates a positive year over year growth rate of 63%. The company is expected to issue its next earnings report on Friday, March 20th.
On average, analysts expect that Stemline Therapeutics will report full year earnings of ($1.77) per share for the current fiscal year, with EPS estimates ranging from ($2.16) to ($1.43). For the next financial year, analysts forecast that the firm will report earnings of ($0.49) per share, with EPS estimates ranging from ($1.36) to $0.53. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Stemline Therapeutics.
Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.08. The business had revenue of $13.33 million for the quarter, compared to analyst estimates of $13.40 million.
STML traded down $0.20 during midday trading on Wednesday, hitting $9.74. 406,187 shares of the company were exchanged, compared to its average volume of 613,687. The company’s 50 day simple moving average is $10.14 and its 200 day simple moving average is $12.19. The firm has a market capitalization of $498.28 million, a price-to-earnings ratio of -3.26 and a beta of 1.38. Stemline Therapeutics has a 1-year low of $7.82 and a 1-year high of $18.22.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhenman & Partners Asset Management AB grew its position in Stemline Therapeutics by 3.4% during the third quarter. Rhenman & Partners Asset Management AB now owns 511,023 shares of the biopharmaceutical company’s stock valued at $5,320,000 after buying an additional 17,024 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Stemline Therapeutics by 51.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,297 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 1,466 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Stemline Therapeutics by 14.0% during the second quarter. Vanguard Group Inc. now owns 1,933,455 shares of the biopharmaceutical company’s stock valued at $29,620,000 after acquiring an additional 237,768 shares during the last quarter. Empire Life Investments Inc. raised its holdings in shares of Stemline Therapeutics by 52.8% during the third quarter. Empire Life Investments Inc. now owns 514,269 shares of the biopharmaceutical company’s stock valued at $5,354,000 after acquiring an additional 177,645 shares during the last quarter. Finally, C WorldWide Group Holding A S lifted its position in shares of Stemline Therapeutics by 16.4% in the third quarter. C WorldWide Group Holding A S now owns 998,677 shares of the biopharmaceutical company’s stock valued at $10,396,000 after acquiring an additional 140,595 shares in the last quarter. 85.00% of the stock is currently owned by hedge funds and other institutional investors.
About Stemline Therapeutics
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
Featured Story: Does the discount rate affect the economy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.